Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Nov;28(5):619–620. doi: 10.1111/j.1365-2125.1989.tb03553.x

The value of therapeutic drug monitoring to the practising physician--an hypothesis needing sensible application.

I D Watson 1, A H Thomson 1
PMCID: PMC1380027  PMID: 2590617

Full text

PDF
619

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bootman J. L., Wertheimer A. I., Zaske D., Rowland C. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost--benefit analysis. J Pharm Sci. 1979 Mar;68(3):267–272. doi: 10.1002/jps.2600680304. [DOI] [PubMed] [Google Scholar]
  2. Destache C. J., Meyer S. K., Padomek M. T., Ortmeier B. G. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. DICP. 1989 Jan;23(1):33–38. doi: 10.1177/106002808902300106. [DOI] [PubMed] [Google Scholar]
  3. Deziel-Evans L. M., Murphy J. E., Job M. L. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986 Apr;5(4):319–324. [PubMed] [Google Scholar]
  4. Ioannides-Demos L. L., Horne M. K., Tong N., Wodak J., Harrison P. M., McNeil J. J., Gilligan B. S., McLean A. J. Impact of a pharmacokinetics consultation service on clinical outcomes in an ambulatory-care epilepsy clinic. Am J Hosp Pharm. 1988 Jul;45(7):1549–1551. [PubMed] [Google Scholar]
  5. Koch-Weser J., Duhme D. W., Greenblatt D. J. Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clin Pharmacol Ther. 1974 Jul;16(1):284–287. doi: 10.1002/cpt1974161part2284. [DOI] [PubMed] [Google Scholar]
  6. Lehmann C. R., Leonard R. G. Effect of theophylline pharmacokinetic monitoring service on cost and quality of care. Am J Hosp Pharm. 1982 Oct;39(10):1656–1662. [PubMed] [Google Scholar]
  7. McInnes G. T. The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing. Br J Clin Pharmacol. 1989 Mar;27(3):281–284. doi: 10.1111/j.1365-2125.1989.tb05365.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mungall D., Marshall J., Penn D., Robinson A., Scott J., Williams R., Hurst D. Individualizing theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes. Ther Drug Monit. 1983;5(1):95–101. [PubMed] [Google Scholar]
  9. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Spector R., Park G. D., Johnson G. F., Vesell E. S. Therapeutic drug monitoring. Clin Pharmacol Ther. 1988 Apr;43(4):345–353. doi: 10.1038/clpt.1988.42. [DOI] [PubMed] [Google Scholar]
  11. Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clin Pharmacokinet. 1987 Sep;13(3):131–140. doi: 10.2165/00003088-198713030-00001. [DOI] [PubMed] [Google Scholar]
  12. Vozeh S. Therapeutic drug monitoring. Clin Pharmacol Ther. 1988 Dec;44(6):713–714. doi: 10.1038/clpt.1988.217. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES